Esperion Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Led by Roger Newton, PhD, the former head of the atherosclerotic research team at Warner-Lambert's Parke-Davis division that discovered and developed {Lipitor}, Esperion Therapeutics Inc. was founded to exploit the reverse cholesterol transport pathway for the development of a new class of anti-cholesterol drugs, starting with a preclinical candidate licensed from Pharmacia & Upjohn Inc. called ApoA-I Milano.
You may also be interested in...
GSK Puts Up (Another) Venture Fund
The name of GlaxoSmithKline's just-launched, $500 million venture fund--GSK Venture Fund--lacks pizzazz, but might do more for the pharma firm on a broader scale than its precursor, SR One. The new effort, which has yet to be formally announced, takes a more conventional--and maybe more assertive--VC approach to nailing down rights and/or starting product- and technology-focused companies.
Torcetrapib: Biomarker for the Big Pharma Business Model
As biotechs often live or die on the success of one pipeline project, so too Pfizer finds itself in the same position. Weak drug launches, intense competition in its core cholesterol franchise, and, analysts say, an unimpressive pipeline. Except torcetrapib--perhaps the most important clinical-stage project in the industry. If it fails, Pfizer's in trouble. If it succeeds, Pfizer will have proven that giantism isn't antithetical to growth.
Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.